Ozempic is a once-a-week GLP-1 analogue designed to improve blood sugar levels. Credit: Natalia Varlei / Shutterstock.com.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has launched a probe into the use of Novo Nordisk’s GLP-1 receptor agonists for diabetes and as a weight-loss treatment.

The GLP-1 receptor agonists under review comprise Ozempic (semaglutide), which is indicated for treating type 2 diabetes (T2D), and Saxenda (liraglutide), which is used as a weight-loss treatment, Reuters reported.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The review was triggered after cases of alleged suicidal or self-harming thoughts were reported in some patients who took these GLP-1 receptor agonists.

In July 2023, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) began investigating the data on the risk of suicidal and self-harming thoughts linked to the use of Ozempic, Saxenda (liraglutide) and Wegovy (semaglutide). 

Wegovy is Novo’s latest obesity treatment and is claimed to have greater effectiveness than Saxenda.

Ozempic has not received approval from the MHRA for use as a weight loss treatment, but it is being used off-label in the UK, the new report noted.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Novo Nordisk is said to have received MHRA’s request on its review of alleged suicidal and self-harming thoughts linked to the drugs in late July 2023.

Novo was quoted by the news agency as saying: “The review is ongoing and a response will be provided within the requested timelines.”

The MHRA is also reviewing AstraZeneca’s Bydureon (exenatide), Sanofi’s lixisenatide and Eli Lilly’s dulaglutide.

AstraZeneca did not respond to a comment request of the news agency while Sanofi and Lilly noted that the companies were aware of the development.

Originally developed to treat T2D, GLP-1 receptor agonists can imitate a gut hormone that can reduce appetite.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact